FDA clears Medtronic nerve ablation device for chronic pain

Medtronic HQ
The Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes. (Medtronic)

Medtronic has received an FDA clearance for its Accurian radiofrequency ablation system for nerve tissues, designed to treat chronic pain through a minimally invasive procedure.

The device uses radio waves to generate heat that burns out small patches of nerves to stop them from sending pain signals—while using advanced software to help control the amount of power delivered and the temperature of the procedure, for more consistent and predictable lesion formations.

According to Medtronic, the Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes to create a range of lesion shapes, sizes and volumes while allowing the physician to control each current channel independently.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Disabling pain lasting more than three to six months affects at least 100 million adults in the U.S., Medtronic said, with related treatment and lost productivity costs reaching $635 billion a year.

RELATED: The top 10 medtech companies of 2024 | Medtronic

The medtech giant previously received FDA approval and a CE mark for its Intellis spinal cord stimulation implant for chronic intractable pain. The neurostimulator also records the patient’s activity and movement, so physicians can track how well the program is treating pain.

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.